Public market insider buying at Knight Therapeutics (T:GUD)

3487911 Canada Inc, a 10% Holder, acquired 22,500 Common Shares on a direct ownership basis at prices ranging from $5.300 to $5.330 between December 3rd, 2020 and December 8th, 2020. This represents a $119,850 investment into the company's shares and an account share holdings change of 0.1%.

In addition, Jonathan Goodman, CEO, Director and 10% Holder, acquired 9,800 Common Shares on a direct ownership basis at a price of $5.270 on December 4th, 2020. This represents a $51,646 investment into the company's shares and an account share holdings change of 2.0%.

Knight Therapeutics is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Knight Therapeutics Inc is a Canada-based specialty pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices. The Company's products are ILUVIEN Fluocinolone acentonid, Nerlynx Neratinib Tablets, Burinex Bumetanide, Probuphine Buprenorphine implant and Movantik Naloxegol.